This study was a retrospective non-interventional cohort study with secondary use of data from the Medical Data Vision (MDV) hospital-based database. The study setting was defined as follows:

• The inclusion period covered 01 February 2015 to 30 September 2020.
• The study period covered 01 August 2014 to 30 September 2021 inclusive.
• The index date was defined as the date of the first prescription of secukinumab or adalimumab within the inclusion period.
• The pre-index period was defined as the 6-month period before the index date (exclusive).
• Patients were followed until death, discontinuation of treatments of interest or end of the study period, whichever occurred first.

Inclusion criteria:

• Having at least one biologic agent prescription of interest (secukinumab or adalimumab - princeps or biosimilars) recorded, in accordance with package insert, during the inclusion period (first prescription: index date).
• Having a confirmed diagnosis of PsA (the international classification of diseases, 10th revision [ICD-10]: L405) (at least 1 inpatient or outpatient claim without any doubtful flag) recorded during the pre-index period or at the index date.
• Being age 18 years or older at the index date.
• Having at least a 6-month pre-index period.

Bio-naive subgroup:

• Patients were considered as bio-naive if no record of any biologic agent prescriptions indicated for psoriasis or PsA (infliximab, adalimumab, certolizumab pegol, ustekinumab, risankizumab, guselkumab, secukinumab, ixekizumab, brodalumab - princeps or biosimilars) were retrieved during the pre-index period.

Exclusion Criteria:

• Having a biologic agent overdose (over 300 mg for secukinumab and over 80 mg for adalimumab) observed during the study period (off-label),
• Having at least one record of secukinumab (for secukinumab patients) or adalimumab (for adalimumab patients) retrieved during the pre-index period.

This was a retrospective, noninterventional cohort study.